FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation

On November 28, 2018, the Food and Drug Administration approved gilteritinib (XOSPATA, Astellas Pharma US Inc.) for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

Source: FDA Center for Drug Evaluation and Research - What's New - July 31, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news